Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2024 Jun 27

PMID 38935188

Authors

Ibrahim Sahin

Okan Bakiner

Tevfik Demir

Ramazan Sari

Aysegul Atmaca

Affiliations

Soon will be listed here.

Abstract

The increasing burden of type 2 diabetes (T2D), in relation to alarming rise in the prevalence; challenges in the diagnosis, prevention, and treatment; as well as the substantial impact of disease on longevity and quality of life, is a major concern in healthcare worldwide. Sulfonylureas (SUs) have been a cornerstone of T2D pharmacotherapy for over 60 years as oral antidiabetic drugs (OADs), while the newer generation SUs, such as gliclazide modified release (MR), are known to be associated with low risk of hypoglycemia in addition to the cardiovascular neutrality. This scoping review aimed to specifically address the current position of gliclazide MR among other SUs in the contemporary treatment paradigm for T2D and to provide a practical guidance document to assist clinicians in using gliclazide MR in real-life clinical practice. The main topics addressed in this paper include the role of early and sustained glycemic control and use of SUs in T2D management, the properties of gliclazide MR in relation to its effectiveness and safety, the use of gliclazide therapy in special populations, and the place of SUs as a class and gliclazide MR specifically in the current T2D treatment algorithm.

Citing Articles

Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes.

Ray A, Paik J, Wexler D, Sreedhara S, Bykov K, Feldman W JAMA Intern Med. 2025; .

PMID: 39928303 PMC: 11811870. DOI: 10.1001/jamainternmed.2024.7811.

Mitochondria and the Repurposing of Diabetes Drugs for Off-Label Health Benefits.

Yip J, Chiang G, Lee I, Lehming-Teo R, Dai K, Dongol L Int J Mol Sci. 2025; 26(1.

PMID: 39796218 PMC: 11719901. DOI: 10.3390/ijms26010364.

Computational studies for pre-evaluation of pharmacological profile of gut microbiota-produced gliclazide metabolites.

danic M, Pavlovic N, Zaklan D, Stanimirov B, Lazarevic S, Al-Salami H Front Pharmacol. 2024; 15:1492284.

PMID: 39691391 PMC: 11649407. DOI: 10.3389/fphar.2024.1492284.

AI-Based Discovery and CryoEM Structural Elucidation of a K Channel Pharmacochaperone.

ElSheikh A, Driggers C, Truong H, Yang Z, Allen J, Henriksen N bioRxiv. 2024; .

PMID: 39282384 PMC: 11398524. DOI: 10.1101/2024.09.05.611490.

References

Downes M, Bettington E, Gunton J, Turkstra E . Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ. 2015; 3:e1461. PMC: 4675096. DOI: 10.7717/peerj.1461. View

Islam N, Ayele H, Yu O, Douros A, Filion K . Sulfonylureas and the Risk of Ventricular Arrhythmias Among People with Type 2 Diabetes: A Systematic Review of Observational Studies. Clin Pharmacol Ther. 2022; 111(6):1248-1257. DOI: 10.1002/cpt.2570. View

White Jr J . A Brief History of the Development of Diabetes Medications. Diabetes Spectr. 2015; 27(2):82-6. PMC: 4522877. DOI: 10.2337/diaspect.27.2.82. View

Khunti K, Chatterjee S, Gerstein H, Zoungas S, Davies M . Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes Endocrinol. 2018; 6(10):821-832. DOI: 10.1016/S2213-8587(18)30025-1. View

. 9. Pharmacologic Approaches to Glycemic Treatment: . Diabetes Care. 2018; 42(Suppl 1):S90-S102. DOI: 10.2337/dc19-S009. View

Hosker J, Rudenski A, Burnett M, Matthews D, Turner R . Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism. 1989; 38(8):767-72. DOI: 10.1016/0026-0495(89)90064-4. View

Daher Vianna A, Lacerda C, Pechmann L, Polesel M, Marino E, Faria-Neto J . A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with.... Diabetes Res Clin Pract. 2018; 139:357-365. DOI: 10.1016/j.diabres.2018.03.035. View

Thule P, Umpierrez G . Sulfonylureas: a new look at old therapy. Curr Diab Rep. 2014; 14(4):473. DOI: 10.1007/s11892-014-0473-5. View

Al-Saleh Y, Sabico S, Al-Furqani A, Jayyousi A, Alromaihi D, Ba-Essa E . Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas. Diabetes Ther. 2021; 12(8):2115-2132. PMC: 8342668. DOI: 10.1007/s13300-021-01059-1. View

10.

Kubota A, Yabe D, Kanamori A, Kuroe A, Takahashi N, Saito T . Factors influencing the durability of the glucose-lowering effect of sitagliptin combined with a sulfonylurea. J Diabetes Investig. 2014; 5(4):445-8. PMC: 4210074. DOI: 10.1111/jdi.12182. View

11.

Wang M, Huang Y, Lai J, Lee C, Wang P, Pan H . Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes. Diabetes Care. 2022; 45(5):1276-1287. DOI: 10.2337/dc21-1779. View

12.

Aravind S, Ismail S, Balamurugan R, Gupta J, Wadhwa T, Loh S . Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012; 28(8):1289-96. DOI: 10.1185/03007995.2012.707119. View

13.

Eroglu T, Jia L, Blom M, Verkerk A, Devalla H, Boink G . Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based study. Br J Clin Pharmacol. 2021; 87(9):3588-3598. PMC: 8453495. DOI: 10.1111/bcp.14774. View

14.

Foley J, Sreenan S . Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res. 2009; 41(12):905-9. DOI: 10.1055/s-0029-1234042. View

15.

Aschner P, Kattah W . Effects of the combination of insulin and gliclazide compared with insulin alone in type 2 diabetic patients with secondary failure to oral hypoglycemic agents. Diabetes Res Clin Pract. 1992; 18(1):23-30. DOI: 10.1016/0168-8227(92)90051-r. View

16.

Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E . Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev. 2007; 23(6):479-84. DOI: 10.1002/dmrr.736. View

17.

Cefalu W, Rosenstock J, LeRoith D, Blonde L, Riddle M . Getting to the "Heart" of the Matter on Diabetic Cardiovascular Disease: "Thanks for the Memory". Diabetes Care. 2016; 39(5):664-7. PMC: 5013718. DOI: 10.2337/dc16-0405. View

18.

Levine R . Sulfonylureas: background and development of the field. Diabetes Care. 1984; 7 Suppl 1:3-7. View

19.

Yu O, Azoulay L, Yin H, Filion K, Suissa S . Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia. Am J Med. 2017; 131(3):317.e11-317.e22. DOI: 10.1016/j.amjmed.2017.09.044. View

20.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View